TEMPUS AI, INC.
StreetZero Signal 62
About TEMPUS AI, INC.
Tempus AI, Inc. is a biotechnology research company that uses artificial intelligence to analyze clinical and molecular data to advance precision medicine. Founded in 2015 and headquartered in Chicago, it went public on NASDAQ under ticker TEM in 2024, raising $410.7 million in its IPO. The company partners with pharmaceutical firms and provides AI-powered diagnostics and insights for oncology and other diseases.
LATEST FUNDINGRule 144
$1.1M
Announced 2026-11-17
TOTAL RAISED$2.75B
IN THE NEWS
EMPLOYEES3800
FOUNDED2015
HQChicago, IL, United States
Industry
Public Equity (NASDAQ)
Tags
AIHealthcareBiotechnologyPublic Company
Investors
Key highlights
- Raised $2.75B total funding across 18 rounds
- Went public in 2024 raising $410.7M in IPO at $37 per share
- Uses AI to analyze medical tests and data for personalized medicine
- Backed by investors including Google, NEA and Baillie Gifford
- Announced acquisition of genetics lab company for $600 million
Ask StreetZero about TEMPUS AI, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account